View source for 5dnx


==Crystal structure of IGPD from Pyrococcus furiosus in complex with (R)-C348==
<StructureSection load='5dnx' size='340' side='right'caption='[[5dnx]], [[Resolution|resolution]] 1.80&Aring;' scene=''>
== Structural highlights ==
<table><tr><td colspan='2'>[[5dnx]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Pyrococcus_furiosus Pyrococcus furiosus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5DNX OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5DNX FirstGlance]. <br>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.8&#8491;</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=5LD:[(2R)-2-HYDROXY-3-(1H-1,2,4-TRIAZOL-1-YL)PROPYL]PHOSPHONIC+ACID'>5LD</scene>, <scene name='pdbligand=MN:MANGANESE+(II)+ION'>MN</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5dnx FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5dnx OCA], [https://pdbe.org/5dnx PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5dnx RCSB], [https://www.ebi.ac.uk/pdbsum/5dnx PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5dnx ProSAT]</span></td></tr>
</table>
== Function ==
[https://www.uniprot.org/uniprot/HIS7_PYRFU HIS7_PYRFU] 
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
Programs of drug discovery generally exploit one enantiomer of a chiral compound for lead development following the principle that enantiomer recognition is central to biological specificity. However, chiral promiscuity has been identified for a number of enzyme families, which have shown that mirror-image packing can enable opposite enantiomers to be accommodated in an enzyme's active site. Reported here is a series of crystallographic studies of complexes between an enzyme and a potent experimental herbicide whose chiral center forms an essential part of the inhibitor pharmacophore. Initial studies with a racemate at 1.85 A resolution failed to identify the chirality of the bound inhibitor, however, by extending the resolution to 1.1 A and by analyzing high-resolution complexes with the enantiopure compounds, we determined that both enantiomers make equivalent pseudosymmetric interactions in the active site, thus mimicking an achiral reaction intermediate.

Mirror-Image Packing Provides a Molecular Basis for the Nanomolar Equipotency of Enantiomers of an Experimental Herbicide.,Bisson C, Britton KL, Sedelnikova SE, Rodgers HF, Eadsforth TC, Viner RC, Hawkes TR, Baker PJ, Rice DW Angew Chem Int Ed Engl. 2016 Oct 17;55(43):13485-13489. doi:, 10.1002/anie.201607185. Epub 2016 Sep 26. PMID:27717128<ref>PMID:27717128</ref>

From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
<div class="pdbe-citations 5dnx" style="background-color:#fffaf0;"></div>
== References ==
<references/>
__TOC__
</StructureSection>
[[Category: Large Structures]]
[[Category: Pyrococcus furiosus]]
[[Category: Baker PJ]]
[[Category: Bisson C]]
[[Category: Britton KL]]
[[Category: Eadsforth TC]]
[[Category: Hawkes TR]]
[[Category: Rice DW]]
[[Category: Rodgers HF]]
[[Category: Sedelnikova SE]]
[[Category: Viner RC]]